RLAY vs. CGEM, SRRK, AUTL, PRME, MESO, IMTX, PROK, HUMA, CRGX, and RGNX
Should you be buying Relay Therapeutics stock or one of its competitors? The main competitors of Relay Therapeutics include Cullinan Therapeutics (CGEM), Scholar Rock (SRRK), Autolus Therapeutics (AUTL), Prime Medicine (PRME), Mesoblast (MESO), Immatics (IMTX), ProKidney (PROK), Humacyte (HUMA), CARGO Therapeutics (CRGX), and REGENXBIO (RGNX). These companies are all part of the "biological products, except diagnostic" industry.
Cullinan Therapeutics (NASDAQ:CGEM) and Relay Therapeutics (NASDAQ:RLAY) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations, community ranking and institutional ownership.
Cullinan Therapeutics has a net margin of 0.00% compared to Cullinan Therapeutics' net margin of -1,263.49%. Relay Therapeutics' return on equity of -28.65% beat Cullinan Therapeutics' return on equity.
Relay Therapeutics received 4 more outperform votes than Cullinan Therapeutics when rated by MarketBeat users. However, 79.55% of users gave Cullinan Therapeutics an outperform vote while only 60.94% of users gave Relay Therapeutics an outperform vote.
Cullinan Therapeutics has higher earnings, but lower revenue than Relay Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Cullinan Therapeutics had 7 more articles in the media than Relay Therapeutics. MarketBeat recorded 11 mentions for Cullinan Therapeutics and 4 mentions for Relay Therapeutics. Cullinan Therapeutics' average media sentiment score of 0.87 beat Relay Therapeutics' score of 0.54 indicating that Relay Therapeutics is being referred to more favorably in the news media.
Cullinan Therapeutics has a beta of -0.01, indicating that its share price is 101% less volatile than the S&P 500. Comparatively, Relay Therapeutics has a beta of 1.68, indicating that its share price is 68% more volatile than the S&P 500.
Cullinan Therapeutics currently has a consensus price target of $32.00, suggesting a potential upside of 32.62%. Relay Therapeutics has a consensus price target of $22.20, suggesting a potential upside of 225.51%. Given Cullinan Therapeutics' higher probable upside, analysts clearly believe Relay Therapeutics is more favorable than Cullinan Therapeutics.
86.3% of Cullinan Therapeutics shares are held by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are held by institutional investors. 6.1% of Cullinan Therapeutics shares are held by insiders. Comparatively, 4.3% of Relay Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Cullinan Therapeutics and Relay Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Relay Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RLAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Relay Therapeutics Competitors List
Related Companies and Tools
